Selecting the Next FDA Commissioner—A PhRMA Perspective - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Selecting the Next FDA Commissioner—A PhRMA Perspective
President Obama's choice for agency leadership should take into account several factors.

Pharmaceutical Technology
Volume 33, Issue 1, pp. 122-121

Qualities in a nutshell. Overall, new FDA leadership will be tasked with deftly implementing recently granted authorities, and prioritizing the allocation of bolstered Congressional appropriations and enhanced user fees paid by America's pharmaceutical research and biotechnology companies. The new commissioner will need to work with diverse partners, including researchers, Congress, the White House, patients and pharmaceutical research companies on such measures as the Critical Path Initiative, which improves the scientific bases for product development and manufacture.

Without question, user fees have helped to provide FDA with the essential tools and staffing it needs to protect and promote the public health. However, like Congressional leaders and the White House, PhRMA recognizes the consequences of the agency's insufficient funding. A strong, well-funded FDA is critical to the health and safety of the American public. The incoming FDA commissioner should embrace the need to advocate for an empowered, fully-funded FDA, with a willingness to request additional Congressional resources and authorities, as needed.

The Reagan-Udall Foundation, for example, provides an important place for industry and regulators to work together on mutually beneficial goals such as improving science, streamlining drug approvals, and leveraging industry experience with cutting-edge research tools. While the research foundation has begun its work through private funding, congressional appropriations are needed for it to fulfill its true promise. Through such efforts, FDA and its new commissioner have the potential to follow the lead of the National Institutes of Health, charting the path and leading important public–private partnerships that help patients live longer, healthier, and more productive lives.

Alan Goldhammer, PhD, is vice-president of scientific and regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA),


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here